Developer docs
API playgroundTry for free, no card

Search company profiles

Nkarta Therapeutics

Full company profile

uuid00039na

Namestring
Nkarta Therapeutics
Legal namestring
Nkarta, Inc.
Websiteurl
nkartatx.com
Company typeenum
Public
Founded yearint
2017
Descriptiontext

Nkarta Therapeutics is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California, developing allogeneic, off-the-shelf natural killer (NK) cell therapies for B cell-mediated autoimmune diseases and hematological malignancies. The company's lead candidate, NKX019, is a CAR-NK cell therapy in which NK cells collected from healthy donors via leukapheresis are activated, engineered to express a CD19-targeting CAR and membrane-bound IL-15 for enhanced persistence, expanded, cryopreserved, and administered off-the-shelf; a second candidate, NKX101, targets NKG2D for acute myeloid leukemia and higher-risk myelodysplastic syndrome. The platform is designed to address limitations of autologous CAR-T therapies, including no observed cases of cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, or graft-versus-host disease higher than Grade 3 in clinical trials, immediate action at therapeutic doses without in-body proliferation, and clearance from the body within weeks. NKX019 is being evaluated in the Ntrust-1 Phase 1 trial in lupus nephritis and the Ntrust-2 Phase 1 trial in systemic sclerosis, inflammatory myopathy, and ANCA-associated vasculitis, with recent FDA protocol amendments extending evaluation to primary membranous nephropathy, myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, and enabling outpatient administration at community research centers by community rheumatologists after only two hours of monitoring.

The company is publicly traded on NASDAQ under the ticker NKTX and has no commercialized products, generating no product revenue to date. Its revenue model is premised on future commercialization of approved cell therapy products, supplemented by non-dilutive capital such as an ARPA-H award of up to $48 million for in vivo cell therapy programs. Capital formation has been conducted through public equity offerings (approximately $230 million in September 2023 and approximately $240.1 million in March 2024), leaving the company with a cash balance of approximately $295.1 million as of Q4 2025 and a disclosed runway into 2029. The company's go-to-market approach combines multicenter clinical trial enrollment at academic medical centers with a planned community channel enabled by FDA outpatient dosing flexibility, targeting both specialty autoimmune centers and community rheumatologists. The intended end customers are patients suffering from lupus nephritis, systemic sclerosis, inflammatory myopathy, ANCA-associated vasculitis, primary membranous nephropathy, myasthenia gravis, and systemic lupus erythematosus, where approximately 7 million affected individuals in the United States represent the company's primary addressable population.

Short descriptiontext

Nkarta Therapeutics is a clinical-stage biopharmaceutical company developing allogeneic, off-the-shelf CAR-NK cell therapies, led by NKX019, which targets CD19 to treat B cell-mediated autoimmune diseases including lupus nephritis, systemic sclerosis, inflammatory myopathy, and ANCA-associated vasculitis.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSouth San Francisco, United States
HQ citystring
South San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
allogeneic cell therapy, CAR-NK therapy, autoimmune disease therapeutics, natural killer cell platform, off-the-shelf immunotherapy
Industry5 codes
PRIMARYHLAAABAD
NK Cell Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAKAFAD
Hematologic Oncology (Leukemia/Lymphoma/Myeloma)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cellular Immunotherapy (Allogeneic CAR-NK)
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1NKX019 Commercialization
TypeOne Time License
Description

Nkarta is a clinical-stage company with no commercialized products. The company is advancing NKX019 through Phase 1 clinical trials for multiple autoimmune diseases. Revenue will be generated through commercialization of approved cell therapy products upon successful clinical development and regulatory approval.

nkartatx.com
2Government Funding
TypeLicensing Royalties
Description

Nkarta received funding from US government through ARPA-H for development of in vivo cell therapy programs targeting autoimmune diseases and cancer, with funding amounts up to $48 million.

fiercebiotech.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1NKX019
Description

Lead CAR-NK cell therapy candidate targeting CD19 for treatment of B cell-mediated autoimmune diseases including lupus nephritis, systemic sclerosis, inflammatory myopathy, and ANCA-associated vasculitis

nkartatx.com
+3 more records
Core offering1 text field

Nkarta develops allogeneic, off-the-shelf CAR-NK cell therapies manufactured from healthy donor NK cells via leukapheresis, engineered to express a CD19-targeting CAR plus membrane-bound IL-15, expanded and cryopreserved for outpatient administration. Its lead candidate NKX019 targets B cell-mediated autoimmune diseases including lupus nephritis, systemic sclerosis, inflammatory myopathy, ANCA-associated vasculitis, primary membranous nephropathy, myasthenia gravis, and SLE; a second candidate NKX101 (NKG2D CAR-NK) is being developed for acute myeloid leukemia.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Deep B-cell depletion demonstrated in clinical trials with B-cell reconstitution observed
+2 more records
Product overview1 text field

Nkarta Therapeutics is a clinical-stage biotechnology company developing allogeneic, off-the-shelf natural killer (NK) cell therapies. The company's lead product is NKX019, a CAR NK cell therapy targeting CD19 for autoimmune diseases. Nkarta also has NKX101, an NKG2D-targeting CAR-NK therapy for hematological malignancies. Both products are manufactured from healthy donor cells and designed for outpatient administration without the need for patient cell collection.

Product and service2 records
1NKX019
CategoryAllogeneic CAR-NK cell therapy (core product)
Description

Allogeneic, off-the-shelf CAR-NK cell therapy targeting the CD19 antigen, engineered with membrane-bound IL-15 to enhance NK cell activity and persistence. Designed to eliminate pathogenic B cells that drive B cell-mediated autoimmune diseases such as lupus nephritis, systemic sclerosis, inflammatory myopathy, ANCA-associated vasculitis, primary membranous nephropathy, myasthenia gravis, and systemic lupus erythematosus.

2NKX101
CategoryAllogeneic CAR-NK cell therapy (core product)
Description

Allogeneic, off-the-shelf NKG2D CAR-NK cell therapy being developed for acute myeloid leukemia (AML) and higher-risk myelodysplastic syndrome (MDS).

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage cell therapy company developing CAR-T (e.g., CABA-201, a CD19 CAR-T) for B-cell-mediated autoimmune diseases including lupus nephritis and other autoimmune indications — directly competing with Nkarta's NKX019 in the same patient populations and with the same deep B-cell depletion mechanism.

TypeDirect peer
Description

Develops off-the-shelf allogeneic gamma-delta T cell therapies (e.g., ADI-001 in autoimmune indications including lupus nephritis) — comparable as an off-the-shelf engineered immune-cell therapy in autoimmune B-cell depletion indications.

TypeDirect peer
Description

Develops autologous CAR-T therapies (e.g., KYV-101, CD19 CAR-T) for autoimmune diseases including lupus nephritis and other B-cell-driven conditions — competing head-to-head with NKX019 in clinical trials, target patient populations, and biologic mechanism.

TypeEmerging player
Description

Develops iPSC-derived allogeneic NK and T cell therapies for cancer and autoimmune indications — comparable in platform approach (engineered off-the-shelf immune cells) and overlapping indication focus.

TypeDirect peer
Description

Allogeneic CAR-T and CAR-NK platform using CRISPR-based gene editing; pivoted toward autoimmune indications with CB-010 — comparable as an engineered allogeneic cell therapy peer pursuing B-cell-driven autoimmune disease.

TypeBroad incumbent
Description

Large allogeneic CAR-T developer with multiple off-the-shelf oncology programs and a broader portfolio than Nkarta's, but uses the same fundamental allogeneic platform approach and competes for the same investor and partnership mindshare.

TypeDirect peer
Description

Pioneer of iPSC-derived, off-the-shelf NK cell therapies (and engineered T cells) for cancer and autoimmune disease. Closest direct peer on modality and platform architecture, with multiple off-the-shelf NK programs historically parallel to Nkarta's NKX101.

TypeDirect peer
Description

Develops in vivo and ex vivo allogeneic CAR-T therapies using ARCUS gene editing for both oncology and autoimmune diseases — comparable as a gene-editing-driven cell therapy company pursuing off-the-shelf and autoimmune applications.

TypeBroad incumbent
Description

Established gene-editing cell therapy company (Casgevy for sickle cell / beta-thalassemia) with broader modality coverage including allogeneic CAR-T and off-the-shelf cell therapies — comparable as an adjacent gene-edited cell therapy platform with autoimmune optionality.

TypeEmerging player
Description

Develops iPSC-derived allogeneic NK and macrophage cell therapies for cancer — directly comparable platform architecture (engineered off-the-shelf NK cells) to Nkarta's allogeneic NK pipeline.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors18 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nkarta Therapeutics

Cellular Immunotherapy (Allogeneic CAR-NK)nkartatx.com

Nkarta Therapeutics is a clinical-stage biopharmaceutical company developing allogeneic, off-the-shelf CAR-NK cell therapies, led by NKX019, which targets CD19 to treat B cell-mediated autoimmune diseases including lupus nephritis, systemic sclerosis, inflammatory myopathy, and ANCA-associated vasculitis.

What Nkarta Therapeutics does

Nkarta Therapeutics is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California, developing allogeneic, off-the-shelf natural killer (NK) cell therapies for B cell-mediated autoimmune diseases and hematological malignancies. The company's lead candidate, NKX019, is a CAR-NK cell therapy in which NK cells collected from healthy donors via leukapheresis are activated, engineered to express a CD19-targeting CAR and membrane-bound IL-15 for enhanced persistence, expanded, cryopreserved, and administered off-the-shelf; a second candidate, NKX101, targets NKG2D for acute myeloid leukemia and higher-risk myelodysplastic syndrome. The platform is designed to address limitations of autologous CAR-T therapies, including no observed cases of cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, or graft-versus-host disease higher than Grade 3 in clinical trials, immediate action at therapeutic doses without in-body proliferation, and clearance from the body within weeks. NKX019 is being evaluated in the Ntrust-1 Phase 1 trial in lupus nephritis and the Ntrust-2 Phase 1 trial in systemic sclerosis, inflammatory myopathy, and ANCA-associated vasculitis, with recent FDA protocol amendments extending evaluation to primary membranous nephropathy, myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, and enabling outpatient administration at community research centers by community rheumatologists after only two hours of monitoring.

The company is publicly traded on NASDAQ under the ticker NKTX and has no commercialized products, generating no product revenue to date. Its revenue model is premised on future commercialization of approved cell therapy products, supplemented by non-dilutive capital such as an ARPA-H award of up to $48 million for in vivo cell therapy programs. Capital formation has been conducted through public equity offerings (approximately $230 million in September 2023 and approximately $240.1 million in March 2024), leaving the company with a cash balance of approximately $295.1 million as of Q4 2025 and a disclosed runway into 2029. The company's go-to-market approach combines multicenter clinical trial enrollment at academic medical centers with a planned community channel enabled by FDA outpatient dosing flexibility, targeting both specialty autoimmune centers and community rheumatologists. The intended end customers are patients suffering from lupus nephritis, systemic sclerosis, inflammatory myopathy, ANCA-associated vasculitis, primary membranous nephropathy, myasthenia gravis, and systemic lupus erythematosus, where approximately 7 million affected individuals in the United States represent the company's primary addressable population.

Nkarta Therapeutics firmographics

Firmographics
Name
Nkarta Therapeutics
Legal name
Nkarta, Inc.
Website
https://nkartatx.com
Company type
Public
Founded year
2017
Operating status
Operating
Headcount range
101–250 employees
Short description
Nkarta Therapeutics is a clinical-stage biopharmaceutical company developing allogeneic, off-the-shelf CAR-NK cell therapies, led by NKX019, which targets CD19 to treat B cell-mediated autoimmune diseases including lupus nephritis, systemic sclerosis, inflammatory myopathy, and ANCA-associated vasculitis.
Ownership category
akta.pro rank

Nkarta Therapeutics industry classification

Industry
Product category
Cellular Immunotherapy (Allogeneic CAR-NK)
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAABAD
NK Cell Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAKAFAD
Hematologic Oncology (Leukemia/Lymphoma/Myeloma)

Keywords

  • Allogeneic cell therapy
  • CAR-NK therapy
  • Autoimmune disease therapeutics
  • Natural killer cell platform
  • Off-the-shelf immunotherapy

Where Nkarta Therapeutics is headquartered

Location

Headquarters

HQ city
South San Francisco
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Nkarta Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. NKX019 Commercialization: Nkarta is a clinical-stage company with no commercialized products. The company is advancing NKX019 through Phase 1 clinical trials for multiple autoimmune diseases. Revenue will be generated through commercialization of approved cell therapy products upon successful clinical development and regulatory approval.
  2. Government Funding: Nkarta received funding from US government through ARPA-H for development of in vivo cell therapy programs targeting autoimmune diseases and cancer, with funding amounts up to $48 million.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Nkarta Therapeutics product offering

Product offering

Core offering

Nkarta develops allogeneic, off-the-shelf CAR-NK cell therapies manufactured from healthy donor NK cells via leukapheresis, engineered to express a CD19-targeting CAR plus membrane-bound IL-15, expanded and cryopreserved for outpatient administration. Its lead candidate NKX019 targets B cell-mediated autoimmune diseases including lupus nephritis, systemic sclerosis, inflammatory myopathy, ANCA-associated vasculitis, primary membranous nephropathy, myasthenia gravis, and SLE; a second candidate NKX101 (NKG2D CAR-NK) is being developed for acute myeloid leukemia.

Product overview

Nkarta Therapeutics is a clinical-stage biotechnology company developing allogeneic, off-the-shelf natural killer (NK) cell therapies. The company's lead product is NKX019, a CAR NK cell therapy targeting CD19 for autoimmune diseases. Nkarta also has NKX101, an NKG2D-targeting CAR-NK therapy for hematological malignancies. Both products are manufactured from healthy donor cells and designed for outpatient administration without the need for patient cell collection.

Differentiator

Problem solved

Functional benefit

Brands

  • NKX019: Lead CAR-NK cell therapy candidate targeting CD19 for treatment of B cell-mediated autoimmune diseases including lupus nephritis, systemic sclerosis, inflammatory myopathy, and ANCA-associated vasculitis
  • NKX101
  • Ntrust-1
  • Ntrust-2

Products and services

  • NKX019 Allogeneic, off-the-shelf CAR-NK cell therapy targeting the CD19 antigen, engineered with membrane-bound IL-15 to enhance NK cell activity and persistence. Designed to eliminate pathogenic B cells that drive B cell-mediated autoimmune diseases such as lupus nephritis, systemic sclerosis, inflammatory myopathy, ANCA-associated vasculitis, primary membranous nephropathy, myasthenia gravis, and systemic lupus erythematosus.
  • NKX101 Allogeneic, off-the-shelf NKG2D CAR-NK cell therapy being developed for acute myeloid leukemia (AML) and higher-risk myelodysplastic syndrome (MDS).

Quantifiable outcome

  • Deep B-cell depletion demonstrated in clinical trials with B-cell reconstitution observed
  • +2 more outcomes

Companies that use Nkarta Therapeutics

Customer profile

Segments3 records

Ideal customer profiles2 records

Nkarta Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Nkarta Therapeutics partnerships and signals

Strategic signal

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Nkarta Therapeutics competitors and assessment

Company assessment

Direct peers

  • Cabaletta Bio: Clinical-stage cell therapy company developing CAR-T (e.g., CABA-201, a CD19 CAR-T) for B-cell-mediated autoimmune diseases including lupus nephritis and other autoimmune indications — directly competing with Nkarta's NKX019 in the same patient populations and with the same deep B-cell depletion mechanism.
  • Adicet Bio: Develops off-the-shelf allogeneic gamma-delta T cell therapies (e.g., ADI-001 in autoimmune indications including lupus nephritis) — comparable as an off-the-shelf engineered immune-cell therapy in autoimmune B-cell depletion indications.
  • Kyverna Therapeutics: Develops autologous CAR-T therapies (e.g., KYV-101, CD19 CAR-T) for autoimmune diseases including lupus nephritis and other B-cell-driven conditions — competing head-to-head with NKX019 in clinical trials, target patient populations, and biologic mechanism.
  • Caribou Biosciences: Allogeneic CAR-T and CAR-NK platform using CRISPR-based gene editing; pivoted toward autoimmune indications with CB-010 — comparable as an engineered allogeneic cell therapy peer pursuing B-cell-driven autoimmune disease.
  • Fate Therapeutics: Pioneer of iPSC-derived, off-the-shelf NK cell therapies (and engineered T cells) for cancer and autoimmune disease. Closest direct peer on modality and platform architecture, with multiple off-the-shelf NK programs historically parallel to Nkarta's NKX101.
  • Precision BioSciences: Develops in vivo and ex vivo allogeneic CAR-T therapies using ARCUS gene editing for both oncology and autoimmune diseases — comparable as a gene-editing-driven cell therapy company pursuing off-the-shelf and autoimmune applications.

Emerging players

  • Century Therapeutics: Develops iPSC-derived allogeneic NK and T cell therapies for cancer and autoimmune indications — comparable in platform approach (engineered off-the-shelf immune cells) and overlapping indication focus.
  • Shoreline Biosciences: Develops iPSC-derived allogeneic NK and macrophage cell therapies for cancer — directly comparable platform architecture (engineered off-the-shelf NK cells) to Nkarta's allogeneic NK pipeline.

Broad incumbents

  • Allogene Therapeutics: Large allogeneic CAR-T developer with multiple off-the-shelf oncology programs and a broader portfolio than Nkarta's, but uses the same fundamental allogeneic platform approach and competes for the same investor and partnership mindshare.
  • CRISPR Therapeutics: Established gene-editing cell therapy company (Casgevy for sickle cell / beta-thalassemia) with broader modality coverage including allogeneic CAR-T and off-the-shelf cell therapies — comparable as an adjacent gene-edited cell therapy platform with autoimmune optionality.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Nkarta Therapeutics social profiles

Digital presence

Nkarta Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nkarta Therapeutics leadership team

Management profile

Number of profiles

Profiles10 records

Nkarta Therapeutics funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nkarta Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nkarta Therapeutics

What does Nkarta Therapeutics do?

Nkarta develops allogeneic, off-the-shelf CAR-NK cell therapies manufactured from healthy donor NK cells via leukapheresis, engineered to express a CD19-targeting CAR plus membrane-bound IL-15, expanded and cryopreserved for outpatient administration. Its lead candidate NKX019 targets B cell-mediated autoimmune diseases including lupus nephritis, systemic sclerosis, inflammatory myopathy, ANCA-associated vasculitis, primary membranous nephropathy, myasthenia gravis, and SLE; a second candidate NKX101 (NKG2D CAR-NK) is being developed for acute myeloid leukemia.

Is Nkarta Therapeutics a public or private company?

Nkarta Therapeutics is a public company. It is classified as public and is currently operating.

When was Nkarta Therapeutics founded?

Nkarta Therapeutics was founded in 2017. It employs 101 to 250 people.

Where is Nkarta Therapeutics based?

Nkarta Therapeutics is headquartered in South San Francisco, United States, in the North America region.

How does Nkarta Therapeutics make money?

Two revenue lines are on record. NKX019 Commercialization is the primary driver. The others are government Funding.

Who are Nkarta Therapeutics's main competitors?

Direct peers on record are Cabaletta Bio, Adicet Bio, Kyverna Therapeutics, Caribou Biosciences, Fate Therapeutics and Precision BioSciences. Emerging players are Century Therapeutics and Shoreline Biosciences. Broad incumbents are Allogene Therapeutics and CRISPR Therapeutics.

Does Nkarta Therapeutics have an API?

No public API is recorded for Nkarta Therapeutics.

What industry is Nkarta Therapeutics in?

Nkarta Therapeutics's product category is Cellular Immunotherapy (Allogeneic CAR-NK). Its primary akta.pro industry code is HLAAABAD, NK Cell Therapies, with a secondary code of HLAAABAB, Cell Therapy Developers (Allogeneic/Off-the-shelf). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewNkarta, Inc. Stock 12‑Month Price Target Raised to $10.8, Implies 839% UpsideAnalysts' average price target for Nkarta, Inc. rose to $10.8 from $10.5, implying about 839% upside from the Nov. 18 close. The consensus remains a Buy across six analysts, with forecasts ranging from $9 to $12 per share.MarketScreenerNkarta Announces Initial Clinical Data For NKX019 In Myositis And Systemic SclerosisNkarta announced positive initial clinical data from its Ntrust trial for NKX019, a CAR NK cell therapy, in myositis and systemic sclerosis. At the 4 billion-cell dose, 83% of myositis patients and 86% of systemic sclerosis patients achieved moderate or major responses. Data are as of September 18, 2026, with continued follow-up planned.AdvfnNkarta Reports Initial NKX019 Clinical Responses in Myositis and Systemic Sclerosis TrialsNkarta reported preliminary NKX019 trial data at ACR 2026, showing 83% of myositis patients and 86% of systemic sclerosis patients achieved responses. No serious adverse events occurred, and the company plans to discuss FDA registration pathways in 2027.Business & FinancialNkarta Announces Initial Clinical Data For NKX019 In Myositis And Systemic Sclerosis At ACR ConvergenceNkarta announced initial clinical data for NKX019 at ACR Convergence, showing 83% of myositis patients and 86% of systemic sclerosis patients achieved meaningful responses at the 4 billion-cell dose. No immune-related toxicities were observed in 40 patients across five indications. The company plans to report additional follow-up and registrational dose selection in 2027.MedCity NewsNkarta Autoimmune Disease Cell Therapy’s First Human Data Show Safety, Signs of EfficacyNkarta reported preliminary data from two small studies of its NK019 cell therapy, showing safety and signs of efficacy in myositis and systemic sclerosis. The therapy, made from healthy donor NK cells engineered to target CD19, was well tolerated across 40 patients with no adverse events. Nkarta plans to meet with the FDA about a potential registrational pathway.YahooNkarta Announces Initial Clinical Data for NKX019 in Myositis and Systemic Sclerosis at ACR ConvergenceNkarta announced positive initial clinical data for NKX019 in myositis and systemic sclerosis at ACR Convergence 2026. In myositis, 5/6 patients (83%) achieved moderate or major responses, and in systemic sclerosis, 6/7 (86%) achieved rCRISS-25 or greater. The company plans to report additional follow-up and registrational dose selection in the first half of 2027.Stock TitanNkarta NKX019: 83% myositis response at 4B doseNkarta announced initial clinical data for NKX019 in myositis and systemic sclerosis, showing 83% of myositis patients and 86% of systemic sclerosis patients achieved moderate or major responses at the 4 billion-cell dose. No immune-related toxicities were observed in 40 patients, and the company plans to discuss registrational pathways with the FDA.Business & FinancialNkarta To Host Webcast To Discuss Initial Clinical Data For NKX019 In Autoimmune Diseases At ACR Convergence 2026Nkarta will host a webcast at ACR Convergence 2026 to present initial clinical data for NKX019 in autoimmune diseases. The Ntrust-1 and Ntrust-2 trials are enrolling up to 12 patients per dose level per indication, with leading indications in myositis and systemic sclerosis. The company aims to evaluate single-agent activity and facilitate a rapid path to regulatory approval.American Banking and Market NewsNkarta, Inc. (NASDAQ:NKTX) Stock Has Average Price Target of $11.20 According to BrokeragesNkarta's stock opened at $1.74, with an average analyst price target of $11.20 and a Moderate Buy rating. The company missed Q2 earnings estimates with a -$0.54 EPS versus -$0.36 expected. Institutional investors hold 80.54% of the stock.MarketBeatNkarta, Inc. (NASDAQ:NKTX) Stock Has Consensus Target Price of $11.20Nkarta's stock received a Moderate Buy consensus from seven analysts, with an average 12-month price target of $11.20. The company reported a Q2 loss of $0.54 per share, missing the $0.36 consensus estimate, and analysts forecast a full-year loss of $1.60 per share.